INTENSITY THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
INTENSITY THERAPEUTICS, INC. (INTS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -1.44M shares, a 326.64% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 60.20K shares, a 95.81% decline from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.44M shares, a 590.33% increase from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 208.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 0.00 shares 10-Q · filed 2026-08-11 | -1.44M shares derived: sum of 3 quarters · filed 2026-08-11 | -1.44M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | -1.44M shares derived: sum of 2 quarters · filed 2026-05-07 | -1.44M shares derived: sum of 3 quarters · filed 2026-05-07 | 60.20K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | -1.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -1.44M shares derived: sum of 2 quarters · filed 2026-03-27 | 60.20K shares derived: sum of 3 quarters · filed 2026-03-27 | 60.20K shares 10-K · filed 2026-03-27 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.50M shares derived: sum of 2 quarters · filed 2025-11-06 | 1.50M shares 10-Q · filed 2025-11-06 | 2.14M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 1.50M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.50M shares 10-Q · filed 2025-08-07 | 2.14M shares derived: sum of 3 quarters · filed 2025-08-07 | 2.14M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-13 | 637.50K shares derived: sum of 2 quarters · filed 2025-05-13 | 637.50K shares derived: sum of 3 quarters · filed 2025-05-13 | 736.50K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 637.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 637.50K shares derived: sum of 2 quarters · filed 2025-03-13 | 736.50K shares derived: sum of 3 quarters · filed 2025-03-13 | 1.44M shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 99.00K shares derived: sum of 2 quarters · filed 2024-11-13 | 798.38K shares 10-Q · filed 2024-11-13 | |
| 2024-06-30 | 99.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 798.38K shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 699.38K shares 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 208.00K shares 10-K · filed 2024-03-14 | |||
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 0.00 shares 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |